46
Growth Score
pts
Heat Score
1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
470246
BryoLogyx is developing a new class of drugs to enhance the response rates and treatment durability of cancer immunotherapies.
- Thomas M. Loarie: Co-Founder, Founding CEO and Board Member
Sam Kongsamut: Vice-President Research and Development
About the Company
BryoLogyx is developing a new class of drugs to enhance the response rates and treatment durability of cancer immunotherapies.
The company is capitalizing on two recent scientific advances: the discovery that a complex natural product, bryostatin, stimulates tumor antigen production to amplify the immune response unleashed by cancer immunotherapy;
and the invention of the first practical synthetic production method for bryostatin and analogs, enabling their availability for commercial development.
